Compare EVI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVI | SGMT |
|---|---|---|
| Founded | 1959 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6M | 169.4M |
| IPO Year | 1995 | 2021 |
| Metric | EVI | SGMT |
|---|---|---|
| Price | $15.34 | $7.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $35.00 | $26.13 |
| AVG Volume (30 Days) | 83.9K | ★ 1.3M |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | ★ 32.43 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $389,830,000.00 | $2,000,000.00 |
| Revenue This Year | $15.53 | N/A |
| Revenue Next Year | $3.83 | N/A |
| P/E Ratio | $49.55 | ★ N/A |
| Revenue Growth | ★ 10.26 | N/A |
| 52 Week Low | $14.06 | $4.50 |
| 52 Week High | $34.82 | $11.41 |
| Indicator | EVI | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 52.37 |
| Support Level | $14.06 | $7.09 |
| Resistance Level | $21.36 | $7.39 |
| Average True Range (ATR) | 0.92 | 0.43 |
| MACD | 0.14 | 0.04 |
| Stochastic Oscillator | 43.90 | 52.14 |
EVI Industries Inc is a value-added distributor and service provider in the commercial laundry industry. It sells and leases commercial laundry equipment, specializing in washing, drying, finishing, material handling, water heating, power generation, and water reuse applications. The company supports its equipment offerings with installation, maintenance, and repair services through a large network of trained technicians. It serves a wide range of customers, including commercial, industrial, institutional, government, and retail sectors. Geographically, the company serves various countries including United States, Canada, the Caribbean, and Latin America.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.